Spots Global Cancer Trial Database for recurrent hepatocellular carcinoma

Every month we try and update this database with for recurrent hepatocellular carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	NCT02867592	Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor	Cabozantinib Cabozantinib S-... Pharmacological...	2 Years - 30 Years	National Cancer Institute (NCI)
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation	NCT03634683	Recurrent Hepat...	LioCyx	21 Years -	Lion TCR Pte. Ltd.
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation	NCT04237740	Hepatocellular ... Liver Transplan...	relenvatinib	18 Years - 75 Years	RenJi Hospital
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant	NCT05103904	Recurrent Hepat... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Laboratory Biom... Lenvatinib	18 Years -	Emory University
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation	NCT03634683	Recurrent Hepat...	LioCyx	21 Years -	Lion TCR Pte. Ltd.
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	NCT02143401	Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So...	Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer	NCT03257761	Extrahepatic Bi... Gallbladder Ade... Metastatic Panc... Recurrent Chola... Recurrent Gallb... Recurrent Hepat... Recurrent Intra... Recurrent Pancr... Stage III Gallb... Stage III Hepat... Stage III Intra... Stage III Pancr... Stage IIIA Gall... Stage IIIA Hepa... Stage IIIB Gall... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Gallbl... Stage IV Hepato... Stage IV Pancre... Stage IVA Gallb... Stage IVA Hepat... Stage IVA Intra... Stage IVB Gallb... Stage IVB Hepat... Stage IVB Intra... Unresectable Ga... Unresectable Pa...	Durvalumab Guadecitabine	18 Years -	University of Southern California
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant	NCT05103904	Recurrent Hepat... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Laboratory Biom... Lenvatinib	18 Years -	Emory University
Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC	NCT05596630	Carcinoma; Hepa...	Stereotactic bo...	18 Years - 80 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC	NCT04615143	Recurrent Hepat...	Tislelizumab Tislelizumab co...	18 Years - 75 Years	Sun Yat-sen University
A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation	NCT02719782	Recurrent Hepat...	Biological: TCR...	21 Years - 65 Years	Lion TCR Pte. Ltd.
Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation	NCT04237740	Hepatocellular ... Liver Transplan...	relenvatinib	18 Years - 75 Years	RenJi Hospital
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)	NCT01318200	Recurrent Hepat...	Transarterial C... CyberKnife SBRT	18 Years -	Accuray Incorporated
Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation	NCT04237740	Hepatocellular ... Liver Transplan...	relenvatinib	18 Years - 75 Years	RenJi Hospital
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant	NCT05103904	Recurrent Hepat... Stage III Hepat... Stage IIIA Hepa... Stage IIIB Hepa... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat... Unresectable He...	Laboratory Biom... Lenvatinib	18 Years -	Emory University
Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma	NCT03609268	Recurrent Hepat... Microwave Ablat... Stereotactic Bo...	microwave ablat... stereotactic bo...	18 Years - 80 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC	NCT04663035	Recurrent Hepat...	Tislelizumab Ablation	18 Years -	Sun Yat-sen University
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer	NCT03655002	Recurrent Hepat... Refractory Live... Stage IV Hepato... Stage IVA Hepat... Stage IVB Hepat...	Cyclophosphamid... Cytokine-based ... Nivolumab	18 Years -	City of Hope Medical Center
TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation	NCT04677088	Recurrent Hepat...	TCR-T cells	18 Years -	First Affiliated Hospital, Sun Yat-Sen University
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization	NCT02762266	Child-Pugh Clas... Child-Pugh Clas... Recurrent Hepat...	Stereotactic Bo... Transarterial C... embolic agent lipiodol	18 Years -	Stanford University
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC	NCT04663035	Recurrent Hepat...	Tislelizumab Ablation	18 Years -	Sun Yat-sen University
Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma	NCT02613156	Recurrent Hepat...	laparoscopic re...	18 Years - 70 Years	Sun Yat-sen University
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	NCT04851119	Colorectal Carc... Endometrial Car... Melanoma Neuroblastoma Ovarian Carcino... Pancreatic Duct... Recurrent Desmo... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Malig... Recurrent Non-H... Recurrent Osteo... Refractory Desm... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Non-... Refractory Oste... Solid Pseudopap... Wilms Tumor	Biospecimen Col... Dual X-ray Abso... Tegavivint X-Ray Imaging	12 Months - 30 Years	Children's Oncology Group
The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC	NCT04800497	Hepatocellular ... Recurrent Hepat... Circulating Tum...	Hepatic resecti...	18 Years -	University of Milano Bicocca
RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	NCT05733598	Locally Advance... Recurrent Hepat... Metastatic Hepa...	RP3 atezolizumab bevacizumab	18 Years -	Replimune Inc.
Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer	NCT04805788	Recurrent Hepat... Stage I Hepatoc... Stage II Hepato... Stage III Hepat...	Proton Stereota... Quality-of-Life...	18 Years -	Mayo Clinic
Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC	NCT05596630	Carcinoma; Hepa...	Stereotactic bo...	18 Years - 80 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: